BiotechTube

N-803 + Tislelizumab + Docetaxel

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NSCLC Stage IV

Conditions

NSCLC Stage IV

Trial Timeline

Oct 1, 2025 → Jan 1, 2029

NCT ID
NCT06745908

About N-803 + Tislelizumab + Docetaxel

N-803 + Tislelizumab + Docetaxel is a phase 3 stage product being developed by ImmunityBio for NSCLC Stage IV. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06745908. Target conditions include NSCLC Stage IV.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06745908Phase 3Recruiting

Competing Products

20 competing products in NSCLC Stage IV

See all competitors
ProductCompanyStageHype Score
Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/CarboplatinWuXi BiologicsPhase 3
74
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
BBP-398 + osimertinibLianBioPhase 1
25
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)BioAtlaPhase 1/2
33
YH42946YuhanPhase 1/2
41
HER3-DXd + HER3-DXd + Osimertinib + Osimertinib + HER3-DXd + HER3-DXd + OsimertinibDaiichi SankyoPhase 1
33
U3-1287 + Erlotinib + PlaceboDaiichi SankyoPhase 1/2
41
DS-1205c + OsimertinibDaiichi SankyoPhase 1
33
Datopotamab deruxtecan (Dato-DXd) + DocetaxelDaiichi SankyoPhase 3
77
Datopotamab deruxtecan + Durvalumab + Carboplatin + AZD2936 + MEDI5752 + AZD7789Daiichi SankyoPhase 1
33
Datopotamab deruxtecan + KEYTRUDA® + Carboplatin + CisplatinDaiichi SankyoPhase 1
33
HER3-DXd (FL-DP) + HER3-DXd (CTM-1 Lyo-DP) + HER3-DXd (CTM-3 Lyo-DP)Daiichi SankyoPhase 1
33
CS-7017 + erlotinibDaiichi SankyoPhase 2
52
gilteritinibAstellas PharmaPhase 1
33
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
52
naquotinib + midazolamAstellas PharmaPhase 1
33
OSI-906 + Erlotinib + PlaceboAstellas PharmaPhase 2
52
ExisulindAstellas PharmaPhase 1/2
41
naquotinibAstellas PharmaPhase 1
33
ASP8273Astellas PharmaPhase 2
52

Other Products from ImmunityBio

NAI + Pembrolizumab + NAI + Nivolumab + Ipilimumab + Pembrolizumab + NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) + Cisplatin/carboplatin and pemetrexed plus pembrolizumab. + Cisplatin/carboplatin and pemetrexed plus atezolizumab. + Carboplatin and paclitaxel plus atezolizumab and bevacizumab. + Carboplatin and nab-paclitaxel plus atezolizumab. + NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxelPhase 3
74
Aldoxorubicin + Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)Phase 3
74
N-803 and BCG + N-803Phase 2/3
62
hAd5-S-Fusion+N-ETSD + Placebo (0.9% (w/v) saline)Phase 2/3
62
Nab-paclitaxel + Cisplatin + 5Fluorouracil + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + GI-4000 + GI-6301 + Aldoxorubicin + Avelumab + ALT-803 + haNK + Docetaxel + carboplatinPhase 2
49